ArticleJournal of medicinal chemistry2020
Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant
Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.Chemical Society reviews · 2026Review
- Structure-Activity Relationship Studies for 1,3,4-Thiadiazole-Based Bacterial Carbonic Anhydrase Inhibitors withJournal of medicinal chemistry · 2026Article
- Bacterial Carbonic Anhydrase Inhibitor CAI0019 Demonstrates Efficacy inACS infectious diseases · 2026Article
- Hyaluronic Acid-Palmitate Nanoparticle Delivery of Carbonic Anhydrase Inhibitors Impairs Growth and Early Metabolism inInternational journal of molecular sciences · 2026Article
- Antibiofilm and antibacterial activity of maslinic acid against Vancomycin-Resistant Enterococci (VRE).PloS one · 2026Article
- Drug Design of Carbonic Anhydrase Inhibitors.Sub-cellular biochemistry · 2026Review
- Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci.Scientific reports · 2025Article
- Hit-to-Lead Optimization of Acetazolamide-Based Bacterial Carbonic Anhydrase Inhibitors with Efficacy In Vivo for Treatment of Vancomycin-Resistant Enterococci Septicemia.Journal of medicinal chemistry · 2025Article
- Antimicrobial Activity of 1,3,4-Thiadiazole Derivatives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multi-faceted exploration of the novel active γ-carbonic anhydrase PaCAγ1 in the human pathogen Pseudomonas aeruginosa.International journal of biological macromolecules · 2025Article
- Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci.European journal of medicinal chemistry · 2025Article
- Pyrazolo-Pyrimidinones with Improved Solubility and Selective Inhibition of Adenylyl Cyclase Type 1 Activity for Treatment of Inflammatory Pain.Journal of medicinal chemistry · 2024Article
- Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-ResistantJournal of medicinal chemistry · 2024Article
- Benzothiadiazinone-1,1-Dioxide Carbonic Anhydrase Inhibitors Suppress the Growth of Drug-ResistantInternational journal of molecular sciences · 2024Article
- Inhibition studies with simple and complex (in)organic anions of the γ-carbonic anhydrase fromJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Inhibition of pathogenic bacterial carbonic anhydrases by monothiocarbamates.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Benzenesulfonamide derivatives asJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Selected strategies to fight pathogenic bacteria.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Carbonic Anhydrase Inhibition as a Target for Antibiotic Synergy in Enterococci.Microbiology spectrum · 2023Article
- Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.Clinical microbiology reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Vancomycin-resistant enterococci (VRE) are the second leading cause of hospital-acquired infections (HAIs) attributed to a drug-resistant bacterium in the United States, and resistance to the frontline treatments is well documented. To combat VRE, we have repurposed the FDA-approved carbonic anhydrase drug acetazolamide to design potent antienterococcal agents. Through structure-activity relationship optimization we have arrived at two leads possessing improved potency against clinical VRE strains from MIC = 2 μg/mL (acetazolamide) to MIC = 0.007 μg/mL (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.